NDA 211672 · Hong Kong
Xenleta
Lefamulin Acetate · Oral · Calculi Dissolution Agent; Anti-coagulant
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Mar 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Aug 19, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
2 Phase 3, 0 recruiting
FAERS reports
17
3 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 22, 2026.
XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. ( 1.1 ) To reduce the development of drug resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Community-Acquired Bacterial Pneumonia (CABP) XENLETA is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae , Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae , Legionella pneumophila , Mycoplasma pneumoniae , and Chlamydophila pneumoniae . 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: XENLETA is an antibacterial drug [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 19, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- XENLETA · LEFAMULIN ACETATE EQ 600MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lefamulin" as an intervention, any sponsor and status, largest first.
- Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With PneumoniaPivotal-lookingCompleted
Nabriva Therapeutics AGIndustry
NCT02813694 · 738 participants · Start Aug 2016 · Primary completion Jan 2018
Drug: lefamulin; Moxifloxacin · For: Community Acquired Pneumonia
Sites: Beverly Hills, California; Fresno, California; Northridge, California · 155 sites in all
- Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With PneumoniaPivotal-lookingCompleted
Nabriva Therapeutics AGIndustry
NCT02559310 · 551 participants · Start Sep 2015 · Primary completion Apr 2017
Drug: lefamulin; Moxifloxacin and 1 more · For: Community Acquired Pneumonia
Sites: Hazard, Kentucky; Shreveport, Louisiana; Minneapolis, Minnesota · 99 sites in all
- Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Pivotal-lookingCompleted
Nabriva Therapeutics AGIndustry
NCT01119105 · 210 participants · Start May 2010 · Primary completion Dec 31, 2010
Drug: BC-3781; BC-3781 and 1 more · For: Bacterial Infections; Infection
Sites: Chula Vista, California; La Mesa, California; Oceanside, California · 9 sites in all
Nabriva Therapeutics AGIndustry
NCT02557789 · 20 participants · Start Jun 2015 · Primary completion Jun 2015
Drug: Lefamulin · For: Healthy
Sites: Nottingham, United Kingdom
Nabriva Therapeutics AGIndustry
NCT05225805 · 13 participants · Start Mar 1, 2022 · Primary completion Sep 20, 2022
Drug: Lefamulin · For: Cystic Fibrosis
Sites: Kansas City, Kansas; Boston, Massachusetts; Valhalla, New York · 6 sites in all
University of WashingtonAcademic, hospital or other
NCT05111002 · 12 participants · Start Apr 22, 2022 · Primary completion Nov 30, 2023
Drug: Lefamulin; Doxycycline · For: Mycoplasma Genitalium Infection
Sites: Seattle, Washington
Nabriva Therapeutics AGIndustry
NCT03131141 · 10 participants · Start Jan 8, 2017 · Primary completion Oct 9, 2017
Drug: BC-3781 · For: Healthy
Sites: Nottingham, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea7
- vomiting4
- nausea3
- product use in unapproved indication3
- abdominal discomfort2
- palpitations2
- pneumonia2
- abdominal pain upper1
- cold sweat1
- death1
- drug ineffective1
- feeling abnormal1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 8 |
| 2021 | 8 |
| 2022 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
Tang HJ, Wang JH, Lai CC · Medicine (Baltimore) 2020 · Clinical Trial, Phase III, Multicenter Study
- Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing.
Wicha WW, Prince WT, Lell C, et al. · J Antimicrob Chemother 2019 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
Sawicki GS, Wicha WW, Hiley TS, et al. · Clin Ther 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
- Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Paukner S, Goldberg L, Alexander E, et al. · J Glob Antimicrob Resist 2022 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.
Amalakuhan B, Echevarria KL, Restrepo MI · Expert Opin Pharmacother 2017 · Systematic Review
- Lefamulin for Mycoplasma genitalium treatment failure in Australia and the USA: a case series and pilot open-label parallel arm randomised trial.
Ramchandani MS, Plummer EL, Parker A, et al. · Sex Transm Infect 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Hong Kong
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.